Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Medical Library, Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Paediatr Anaesth. 2023 Aug;33(8):598-608. doi: 10.1111/pan.14674. Epub 2023 Apr 19.
There has been a recent focus among anesthesiologists on reducing the use of perioperative opioids in favor of multimodal analgesic regimens. Gabapentin has played an integral role in this evolution of practice. This comprehensive review assesses the current clinical evidence on the efficacy of perioperative gabapentin regarding postoperative pain and opioid requirements among the pediatric surgery population.
Pubmed, CINAHL, Embase, Scopus, and Web of Science Review.
This scoping review of the above databases includes all studies examining the use of gabapentin perioperatively in pediatric patients and its association with postoperative pain intensity and postoperative opioid consumption through July 2021. The inclusion criteria encompassed all studies evaluating gabapentin in the perioperative pediatric population through randomized controlled trials (RCTs) and retrospective studies. Relevant metadata from each study were abstracted and descriptive statistics were used to summarize the results.
Fifteen papers met the inclusion criteria for this review, including 11 RCTs and 4 retrospective studies. Sample sizes ranged from 20 to 144 patients. Administered doses varied widely, mainly between 5 and 20 mg/kg. The studies included primarily orthopedic (10) and neck surgery cases (3). Seven papers had gabapentin provided preoperatively only, two postoperative only, and six both pre- and postoperatively. Of the studies assessing postoperative pain, 6/11 studies saw a decrease in postoperative pain in at least one period for the gabapentin group. Of the studies considering opioid requirements, 6/10 reported a reduction, 1/10 an increase, and 3/10 no difference in opioid requirements for the gabapentin groups. Yet, most of these pain and opioid requirement findings were only significant at one to two time points in the study follow-up periods, and the actual decreases had minimal clinical significance.
The current data on perioperative gabapentin in pediatric patients are insufficient to support the routine use of gabapentin in pediatric patients. Additional high-quality RCTs with more standardized protocols for gabapentin administration and outcome measures are necessary to provide more definitive conclusions.
麻醉师最近关注的重点是减少围手术期阿片类药物的使用,转而采用多模式镇痛方案。加巴喷丁在这一实践的演变中发挥了不可或缺的作用。本综述评估了围手术期加巴喷丁在儿科手术人群中的术后疼痛和阿片类药物需求方面的临床疗效的现有临床证据。
Pubmed、CINAHL、Embase、Scopus 和 Web of Science 综述。
对上述数据库进行了范围广泛的回顾,包括所有研究都检查了围手术期使用加巴喷丁在儿科患者中的作用及其与术后疼痛强度和术后阿片类药物消耗的关系,截止到 2021 年 7 月。纳入标准包括通过随机对照试验 (RCT) 和回顾性研究评估围手术期儿科人群中使用加巴喷丁的所有研究。从每项研究中提取相关元数据并使用描述性统计来总结结果。
15 篇论文符合本综述的纳入标准,包括 11 项 RCT 和 4 项回顾性研究。样本量从 20 例到 144 例不等。给予的剂量差异很大,主要在 5 至 20mg/kg 之间。这些研究主要包括骨科 (10 例) 和颈部手术病例 (3 例)。有 7 篇论文仅在术前给予加巴喷丁,2 篇仅在术后给予,6 篇同时在术前和术后给予。在评估术后疼痛的研究中,11 项研究中有 6 项至少在加巴喷丁组的一个时期内看到术后疼痛减轻。在考虑阿片类药物需求的研究中,10 项研究中有 6 项报告加巴喷丁组的阿片类药物需求减少,1 项报告增加,3 项报告无差异。然而,这些疼痛和阿片类药物需求发现仅在研究随访期间的一到两个时间点具有统计学意义,实际减少量具有最小的临床意义。
目前关于儿科患者围手术期加巴喷丁的数据不足以支持在儿科患者中常规使用加巴喷丁。需要更多高质量的 RCT,对加巴喷丁的给药和结果测量制定更标准化的方案,以提供更明确的结论。